Analyzing Passage Bio (NASDAQ:PASG) & JATT Acquisition (NYSE:JATT)

Passage Bio (NASDAQ:PASG) and JATT Acquisition (NYSE:JATT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, dividends, institutional ownership and profitability.

Institutional and Insider Ownership

53.5% of Passage Bio shares are owned by institutional investors. Comparatively, 48.0% of JATT Acquisition shares are owned by institutional investors. 4.3% of Passage Bio shares are owned by insiders. Comparatively, 20.0% of JATT Acquisition shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Passage Bio and JATT Acquisition’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Passage Bio	N/A	-72.53%	-52.10%
JATT Acquisition	N/A	-49.58%	2.84%

Earnings and Valuation

This table compares Passage Bio and JATT Acquisition”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Passage Bio	N/A	N/A	-$102.06 million	($1.17)	-0.51
JATT Acquisition	N/A	N/A	$6.85 million	N/A	N/A

Analyst Ratings

This is a summary of recent ratings for Passage Bio and JATT Acquisition, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Passage Bio	0	0	4	0	3.00
JATT Acquisition	0	0	0	0	0.00

Passage Bio presently has a consensus price target of $7.75, suggesting a potential upside of 1,198.16%. Given Passage Bio’s stronger consensus rating and higher possible upside, analysts plainly believe Passage Bio is more favorable than JATT Acquisition.

About Passage Bio

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

About JATT Acquisition

JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.